Results 71 to 80 of about 12,194 (220)

Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis

open access: yesFrontiers in Immunology
ObjectiveCysteamine, a drug approved to treat cystinosis, has been proposed as a host-directed therapy for M. tuberculosis (Mtb) and SARS-CoV-2. The impact of cysteamine on the immune responses has not been fully investigated.
Saeid Najafi-Fard   +14 more
doaj   +1 more source

Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis

open access: yesOrphanet Journal of Rare Diseases, 2022
Background Cystinosis is a rare autosomal recessive lysosomal storage disease, associated with high morbidity and mortality. Mutations in the CTNS gene disable a membrane protein responsible for the transport of cystine out of the lysosome.
Emma Hector   +2 more
doaj   +1 more source

From Selye’s and Szabo’s Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities

open access: yesPharmaceuticals, 2023
We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients.
Predrag Sikiric   +24 more
doaj   +1 more source

2D van der Waals System Integrated with Targeting Radio‐Diagnostic and Imaging Functions

open access: yesSmall, EarlyView.
Layered double hydroxide (LDH) nanoplates were engineered for tumor‐targeted imaging and therapy. By exploiting folate receptor (FR) expression levels, the system achieves selective tumor accumulation and high‐resolution dual PET/fluorescence (PET/FL) imaging.
Sairan Eom   +6 more
wiley   +1 more source

Formulation study of cysteamine microparticulate systems

open access: yes, 2020
Cysteamine is clinically used for the treatment of nephropathic cystinosis and is orally administered as cysteamine bitartrate. The daily dose of cysteamine (Cystagon®) for treatment of cystinosis in paediatric patients is 50 mg/kg per day, shared in ...
ADORNI, GRETA
core   +1 more source

Quantitative Imaging of Human Hemoglobin Binding to Staphylococcus aureus With Single‐Molecule Resolution

open access: yesSmall, EarlyView.
Single‐molecule localization microscopy is exploited to quantify the number of hemoglobin copies bound to specific receptors on S. aureus wall. This quantification supports the design of a photoactive derivative of hemoglobin able to photo‐inactivate S.
Pietro Delcanale   +10 more
wiley   +1 more source

Thiol-SAM Concentration Effect on the Performance of Interdigitated Electrode-Based Redox-Free Biosensors

open access: yesMicromachines
Despite the direct, redox-free and simple detection non-faradaic impedimetric biosensors offer, considerable optimizations are required to enhance their performance for the detection of various biomarkers. Non-faradaic EIS sensors’ performance depends on
Abdulaziz K. Assaifan
doaj   +1 more source

Nanopore and Self‐Assembled Monolayer Engineering of l‐Lactate Oxidase Gold Electrodes for Enhanced l‐Lactate Biosensing

open access: yesSmall, EarlyView.
A tiered nanoporous gold biointerface enables site‐directed immobilization of His‐tagged lactate oxidase through a mixed self‐assembled monolayer, achieving high enzyme loading while preserving activity. The resulting bioelectrode provides sensitive and stable l‐lactate detection (0.12–3.0 mM, 75 µA mM−1 cm−2), demonstrating a modular strategy for high‐
Mislav Sušac   +6 more
wiley   +1 more source

Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate [PDF]

open access: yes, 2012
Halitosis due to dimethylsulfide (DMS) generation is a major side effect of cysteamine in the treatment of cystinosis. Recently, an enteric coated formulation of cysteamine bitartrate (RP103) administered twice daily was demonstrated to be non-inferior ...
Levtchenko, Elena   +4 more
core   +1 more source

Successful treatment of solar lentigines by topical application of stabilized cysteamine: A vehicle‐controlled, double‐blind randomized study

open access: yesHealth Science Reports
Background Solar lentigines are common hyperpigmented lesions typically appearing after 50 years of age and associated with negative psychological effects in affected individuals. Topical depigmenting products, such as hydroquinone and even the Kligman's
Nasrin Saki   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy